BMO Capital Maintains Outperform on AstraZeneca, Raises Price Target to $83
Portfolio Pulse from richadhand@benzinga.com
BMO Capital analyst Etzer Darout has maintained an Outperform rating on AstraZeneca (NASDAQ:AZN) and raised the price target from $81 to $83.
August 01, 2023 | 12:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AstraZeneca's price target has been raised from $81 to $83 by BMO Capital, maintaining an Outperform rating.
The raised price target and maintained Outperform rating by BMO Capital indicates a positive outlook for AstraZeneca. This could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100